Intrathecal Rituximab in Treating Patients With Recurrent CNS Lymphoma

Phase 1 Completed 10 enrolled University of California, San Francisco

Non-randomizedSingle-groupOpen-labelTreatment

Summary

RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving rituximab intrathecally may be an effective treatment for recurrent CNS lymphoma. PURPOSE: This phase I trial is studying the side effects and best dose of intrathecal rituximab in treating patients with recurrent CNS lymphoma.

Timeline

Start: 2002-08
Primary completion: 2005-11
Completion: 2007-04

Publications

Results Rubenstein JL, Fridlyand J, Abrey L, Shen A, Karch J, Wang E, Issa S, Damon L, Prados M, McDermott M, O'Brien J, Haqq C, Shuman M. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol. 2007 Apr 10;25(11):1350-6. doi: 10.1200/JCO.2006.09.7311. Epub 2007 Feb 20.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rituximab	Monoclonal antibody	10 mg	Intrathecal
Subject	Rituximab	Monoclonal antibody	25 mg	Intrathecal
Subject	Rituximab	Monoclonal antibody	50 mg	Intrathecal

Intrathecal Rituximab in Treating Patients With Recurrent CNS Lymphoma

Summary

Timeline

Publications

Drugs

Indications